- Trial Phase
- Phase 2b
- Time to Market
- At least 3-5 years if Phase 2b and subsequent Phase 3 trials succeed
- Why 5/10
- The next hard, dated catalyst is the Phase 2b knee osteoarthritis topline readout, expected Q2-Q3 2027 (~9-15 months away). No PDUFA or FDA approval decision is pending. With the readout ~12 months out and Allocetra as the lead pipeline asset at a company burdened by heavy dilution and a confusing crypto-treasury strategy, the score is capped at 5 — a material but not imminent binary event.
Allocetra's Phase 2a data in knee OA is intriguing (72% pain reduction in elderly patients), but the Phase 2b trial is only now starting enrollment with topline data not expected until mid-2027. Separately, ENLV's stock is heavily influenced by its RAIN token treasury (~$1.14B in tokens vs ~$127M market cap) — this crypto overlay makes the stock more a prediction-markets proxy than a pure biotech play. Watch for Phase 2b enrollment updates and RAIN token price volatility.
Price Chart
Executive Summary
Allocetra is Enlivex's lead pipeline asset — an off-the-shelf, macrophage-reprogramming cell therapy targeting a huge unmet need in knee osteoarthritis (a $314B longevity market with no approved disease-modifying drugs). Phase 2a data showed statistically significant pain reduction (up to 72% in patients aged 60+) and functional improvement sustained at 6 months. The Phase 2b trial was cleared by the FDA and Danish regulators in early 2026, with first patients expected mid-2026 and topline data ~12 months out. However, ENLV is a micro-cap ($127M equity) with a history of heavy dilution (252M shares pre-reverse split, 1:15 reverse split announced July 2026) and a highly unusual treasury strategy holding ~$1.14B in RAIN prediction-market tokens — making the stock hard to value as a pure biotech. Past Phase 2 success does not guarantee Phase 2b success, and the long timeline means shareholders face years of dilution risk.
How It Works
Allocetra is an off-the-shelf cell therapy made from donor white blood cells that are pushed into a natural 'dying' (apoptotic) state. When injected into the body, these cells act as a decoy that gets consumed by macrophages (a type of immune cell). This process 'reprograms' overactive, inflammatory macrophages back to a calm, healthy state, calming inflammation at the source rather than just masking symptoms.
Trial Status
Allocetra completed a Phase 1/2a trial (NCT06233474) in knee OA with positive 3-month and 6-month data. The Phase 2b trial (NCT07580716) — a global, randomized, double-blind, placebo-controlled study in moderate-to-severe age-related knee OA — received FDA IND clearance (March 2026) and Danish Medicines Agency approval (April 2026). First patient dosing is expected mid-2026, with topline data anticipated Q2-Q3 2027. The company also has earlier-stage programs in sepsis, COVID-19 ARDS, and solid tumors.
The Two-Sided Case
Upcoming Catalysts
- Phase 2b knee OA trial initiation / first patient dosed (mid-2026)
- Phase 2b topline data readout (expected Q2-Q3 2027)
- OARSI/ACR conference presentations of Phase 2a data
- RAIN token exchange listings and treasury valuation updates
- Q2 2026 earnings report
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Enlivex Ltd. 6-K ENLV ·Originating report